Amwell (AMWL) Q2 2025: Subscription Software Revenue Jumps 47% as Cost Resets Take Hold
Amwell’s Q2 marked a decisive shift in business mix, with subscription software revenue surging and cost discipline accelerating EBITDA improvement. The extension of the Military Health System (MHS) contract underpins recurring revenue, but budget-driven scope reductions signal ongoing federal funding volatility. Management’s focus on margin expansion and AI-enabled efficiency is reshaping both operational structure and the path to cash flow breakeven in 2026.
Summary
- Revenue Mix Transformation: Subscription software now dominates as Amwell pivots from legacy services toward higher-margin SaaS contracts.
- Federal Contract Volatility: MHS extension supports stability, but behavioral and automated care program exclusions expose budget-driven risk.
- AI and Cost Focus: Management’s operational streamlining and AI adoption drive margin gains and reinforce the 2026 cash flow target.
Performance Analysis
Amwell delivered a standout quarter for software-led growth, with subscription software revenue climbing 47% year-over-year to $40.4 million, now representing 57% of total revenue. This shift was powered by the expanded Military Health System deployment, which also contributed non-recurring revenue tied to implementation milestones. Total revenue reached $70.9 million, up 13% YoY, but the composition is increasingly software-centric—a strategic pivot from Amwell’s legacy visit-based and professional services businesses.
Cost resets across the organization accelerated margin expansion and EBITDA improvement. Gross margin rose to 56.1%, up 3.3 points sequentially, reflecting the higher software mix and ongoing cost initiatives. R&D, sales and marketing, and G&A expenses all fell sharply, with sales and marketing down 32% YoY and G&A down nearly 26%. Adjusted EBITDA improved to negative $4.7 million, a dramatic swing from negative $35 million a year ago, as Amwell’s focus on operational discipline and mix shift began to materialize in the P&L.
- Visit Revenue Decline: AMG visit revenue fell 21% YoY, but normalized for the APC divestiture, visits were flat, with a favorable mix shift toward virtual primary care and specialty programs.
- Cash Burn Reduction: Quarterly cash burn dropped to $3 million, leaving Amwell with $219 million in cash and no debt, supporting runway for continued transformation.
- Guidance Reset: Full-year revenue guidance was lowered to $245–$250 million, reflecting the exclusion of behavioral and automated care from the MHS extension, but EBITDA guidance improved, now projecting a 65% YoY improvement.
Management’s narrative emphasizes the pivot to recurring, high-margin software revenue, but federal contract scope changes and visit volume normalization highlight the ongoing transition risk as Amwell repositions for tech-enabled care leadership.
Executive Commentary
"Our focus and execution are strong as we deliver on key strategies and financial initiatives. They support our guidance and path to accomplishing our goal of positive cash flow from operations in 2026."
Dr. Ido Schoenberg, Chairman and CEO
"Subscription software revenue was 57% of total revenue at $40.4 million, up 47% from a year ago... We are targeting meaningful margin expansion this year, and with another strong EBITDA performance under our belts in Q2, we take a step closer to our goal to improve our adjusted EBITDA by over 60% this year as compared to 2024."
Mark Hirshhorn, CFO and COO
Strategic Positioning
1. Subscription Software Mix Shift
Amwell’s business model is rapidly transitioning from transactional visit revenue to recurring SaaS (Software-as-a-Service) contracts. The MHS contract, now extended, cements Amwell’s platform as critical infrastructure for federal telehealth. With subscription software now the majority of revenue, Amwell is less exposed to volatile visit volumes and is building a more predictable, scalable base for future growth.
2. Federal Market Beachhead and Budget Risk
The MHS contract extension validates Amwell’s execution at scale, but the exclusion of behavioral and automated care programs due to Department of Defense budget constraints exposes the company to federal funding cycles and scope volatility. Management frames these as temporary, with strong conviction in eventual re-inclusion, but the near-term impact is a lower revenue run-rate and a reminder of dependency risk in government verticals.
3. Operational Discipline and AI Enablement
Cost structure transformation is a central theme, with R&D, sales and marketing, and G&A all reset lower. Amwell is leveraging AI to streamline operations, as seen with the launch of Amwell Navigate, a self-service digital customer experience. This operational shift is designed to both reduce costs and improve client support, reinforcing the company’s path to cash flow breakeven in 2026.
4. Pipeline Growth and Platform Stickiness
New wins such as Florida Blue and renewals with key health systems signal that Amwell’s unified, white-labeled platform is resonating with both payers and providers. The ability to integrate third-party clinical programs and provide a seamless member experience is positioned as a key differentiator, driving stickiness and expansion potential within existing accounts.
5. Margin Expansion and Profitability Roadmap
Management is targeting over 60% EBITDA improvement in 2025, driven by the software mix shift and aggressive cost actions. The company’s cash position and reduced burn provide a buffer for continued investment in platform capabilities and government/commercial pipeline development, as Amwell seeks to exit 2026 cash flow positive.
Key Considerations
This quarter underscores a pivotal business model evolution, with Amwell executing a deliberate shift to software and platform economics while managing federal contract complexity and accelerating cost takeout. Investors should weigh the durability of these trends against ongoing federal budget and visit volume risks.
Key Considerations:
- Federal Contract Scope Changes: Exclusion of behavioral and automated care programs from the MHS extension highlights exposure to government budget cycles and the unpredictable timing of program re-inclusion.
- Software Mix Drives Margin: Higher subscription software mix is now the dominant revenue driver, supporting gross margin and EBITDA improvement, but non-recurring implementation revenue contributed to Q2 upside.
- AI-Driven Operational Efficiency: AI adoption and digital self-service are reducing cost structure and improving scalability, but require continued investment and execution discipline.
- Pipeline and Renewal Momentum: Wins with Florida Blue and renewals with key health systems validate platform strategy and support long-term expansion, but commercial pipeline conversion remains critical.
Risks
Amwell remains exposed to federal budget volatility, as evidenced by the MHS program scope reduction, and visit revenue normalization could pressure top-line growth if software expansion slows. The company’s ability to deliver on further cost takeout and sustain pipeline momentum is critical, especially as non-recurring government implementation revenue tapers. Execution risk in AI deployment and integration complexity for third-party programs are also material watchpoints.
Forward Outlook
For Q3 2025, Amwell guided to:
- Revenue of $53 to $56 million
- Adjusted EBITDA of negative $15 to negative $13 million
For full-year 2025, management lowered guidance to:
- Total revenue of $245–$250 million (was $250–$260 million)
- Subscription software revenue to comprise 53% of total (up from 45% in 2024)
- Adjusted EBITDA narrowed to negative $50 to negative $45 million, a 65% YoY improvement
Management highlighted ongoing R&D, sales and marketing, and G&A cost reductions, with R&D down over 10% and G&A down over 20% YoY. The company reaffirmed its goal to end 2025 with $190 million in cash and to achieve cash flow breakeven from operations during 2026.
- Continued margin expansion is expected from software mix
- Pipeline conversion and federal contract stability are key to hitting long-term targets
Takeaways
Amwell’s Q2 marks a clear inflection toward a SaaS-first healthcare platform, but federal contract volatility and ongoing visit normalization create a complex backdrop for the growth narrative.
- Business Model Reset: The pivot to subscription software is driving gross margin and EBITDA improvement, but the sustainability of non-recurring government revenue is a watchpoint.
- Contract and Pipeline Execution: MHS extension provides a platform for future government expansion, but commercial pipeline conversion and program re-inclusion are critical to offsetting federal funding risk.
- 2026 Cash Flow Target: Achieving operational cash flow breakeven hinges on continued cost discipline, successful AI-driven efficiency, and further SaaS revenue expansion.
Conclusion
Amwell’s strategic transition to a software-led, AI-enabled platform is delivering tangible margin and EBITDA gains, but the path forward requires careful navigation of federal contract dynamics and pipeline execution. Investors should monitor the pace of recurring software growth and the company’s ability to deliver on its 2026 cash flow milestone.
Industry Read-Through
Amwell’s quarter highlights the growing importance of SaaS economics and platform integration in digital health, with federal contracts serving as both a growth lever and a source of volatility. The exclusion of behavioral and automated care from the MHS extension signals that even well-performing tech-enabled care programs are subject to government budget cycles. For peers in the telehealth and health IT sector, the pivot to recurring software revenue, operational AI adoption, and cost discipline are increasingly non-negotiable for sustainable growth and margin expansion. The ability to serve as a unified, white-labeled platform for payers and providers is emerging as a key competitive differentiator as the industry shifts toward integrated, whole-person care models.